Venus Remedies share price, P/E, ROE & financials

Venus Remedies (VENUSREM) had a P/E of 15.9× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 29% below their 52-week high. Sales and net profit grew 9.9% and 57% a year over 3 years; its ROCE of 19% is the second-highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 0.7%. It is a small-cap company with a market cap of ₹1,937 Cr, ranked 60th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 227% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹1,522.30
Day high: ₹1,522.30
Day low: ₹1,420.00
Prev. close: ₹1,449.90
Volume: 40.5K

Health check

4 good · 2 fair

ReturnsAhead
+227.1% over a year, better than 7 of 7 peers.
Price tagCheaper
P/E 15.9 vs industry 28.7.
GrowthSteady
Sales +9.9%, profit +57.0% a year over 3 years.
ProfitabilityAverage
ROCE 19.4% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,937 Cr, #60 of 154 in its industry by size.

Defensive

Beta 0.45 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹837 Cr · profit ₹122 Cr

Market cap: ₹1,937 Cr; Small cap
P/E: 15.9; Industry 28.7
Price to book: 2.75; Peers 4.99
Dividend yield: 0.69%
ROE: 18.7%; Peers 14.7%
ROCE: 19.4%; Peers 17.9%
Debt to equity: 0.02; Debt ₹12 Cr
EPS (TTM): ₹91.04; Face value ₹10
OPM (TTM): 21.2%; Net margin 14.5%
Sales growth: +13.5%; Latest quarter vs a year ago
Profit growth: +27.4%; Latest quarter vs a year ago
Price to sales: 2.31; EV/EBITDA 10.9

Strengths

Return on equity of 18.7%.
Practically debt-free.
Quarterly profit up 27.4% on a year ago.
P/E of 15.9 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Venus Remedies

Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS,…

Headquarters: Panchkula
Employees: 1,472
Sector: Healthcare
ISIN: INE411B01019
Website: venusremedies.com

Price range

52 weeks

₹441.65₹2,044.30

Today

₹1,420.00₹1,522.30

Avg volume (3M): 37.6K
1-year return: plus 227.1%
From 52-week high: minus 29.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
VENUSREMVenus Remedies	1,447.70	minus 0.15%	1,937	15.9	2.75	19.4%	18.7%	21.2%	9.9%	57.0%	0.69%	plus 227.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
193	180	259	179	219
162	143	196	145	176
31	37.5	63.4	34.2	42.5
16.1%	20.8%	24.4%	19.1%	19.4%
1.7	2.5	5	2.6	0.5
0	0	0	–	–
6.2	6.6	6.8	6.8	9.5
26.5	33.5	61.6	30	33.5
24.0%	23.6%	22.9%	23.5%	23.4%
20.1	25.6	47.5	23	25.7
15.06	19.14	35.53	17.18	19.19

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +9.9%
Profit CAGR 3Y: +57.0%
EPS CAGR 3Y: +57.0%
ROE: 18.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
553	591	647	735
–	+6.9%	+9.4%	+13.5%
493	532	584	602
60	59.6	63.5	132
10.8%	10.1%	9.8%	18.0%
10.3	11	19.3	21.6
0.1	0.1	0.1	0
32.3	26.4	22.5	25.7
0	0.6	11.5	5.9
37.9	44.6	71.8	134
30.0%	36.2%	36.9%	23.4%
26.6	28.5	45.3	103
–	+7.2%	+59.1%	+126.8%
19.88	21.31	33.90	76.90

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.4	13.4	13.4	13.4
447	474	548	650
42.3	41.3	1.7	12.4
98.5	97.9	153	178
601	627	716	854
164	155	154	193
67.2	22	28.9	55.3
–	0	54.8	164
72.1	83.8	101	98.9
298	366	377	343
601	627	716	854

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
36.6	37.3	86.4	156
−50.8	−7.2	−76.2	−182
−0.6	−1.1	−1	−3.1
−14.8	29	9.2	−28.9
−7.8	−13.5	−18.1	−37.7
28.8	23.8	68.4	118

Shareholding pattern

Source: NSE filings

41.8%

promoters

Promoters41.76%
Public58.24%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	41.76%	58.24%	0.00
30 Jun 2026	41.76%	58.24%	0.00
31 Mar 2026	41.76%	58.24%	0.00
31 Dec 2025	41.76%	58.24%	0.00
30 Sep 2025	41.76%	58.24%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you